In memory
What Irrfan Khan's Story Can Help Us Understand About Neuroendocrine Tumors
The beloved actor shared his neuroendocrine tumor diagnosis in 2018 and died in 2020. Here is what that diagnosis means, explained calmly and simply.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
On screen and in the news
Irrfan Khan, one of India's most acclaimed actors — known internationally for films such as The Lunchbox, Life of Pi, and Slumdog Millionaire — publicly shared in March 2018 that he had been diagnosed with a neuroendocrine tumor. He traveled abroad for treatment and later returned to work before his death in April 2020 at age 53.
That is what was publicly shared. We share it with respect and do not speculate about any private details of his diagnosis or care.
The reality
Irrfan Khan's diagnosis brought unusual public attention to a less common kind of cancer. According to the National Cancer Institute, the pancreas contains two kinds of cells: exocrine cells and neuroendocrine cells, such as islet cells. Cancer can develop from either. Pancreatic neuroendocrine tumors (also called islet cell tumors) are less common than the more familiar exocrine type, and NCI notes they generally have a better prognosis.
Neuroendocrine cells are found in several parts of the body, and NCI describes pancreatic neuroendocrine tumors as one of the distinct forms of pancreatic cancer, with their own treatment information separate from the more common exocrine type.
What the story gets right — and what to remember
Irrfan Khan chose to speak openly about having a rare tumor, which helped many people first hear the term "neuroendocrine." His story is a reminder that cancer is not one single disease — it is many, each behaving differently. Every person's diagnosis and circumstances are different, and a public figure's experience is not medical advice or a prediction for anyone else.
Awareness, screening & prevention
NCI states that it does not have PDQ evidence-based information about routine screening for pancreatic cancer in people at average risk, and it does not have PDQ evidence-based prevention information for this cancer. Because early disease can be quiet, bringing persistent, unexplained symptoms to a healthcare professional is a sensible step at any age. People with a strong family history or certain inherited conditions may have a different conversation with their care team.
Turning a story into something useful
Remembering someone through learning is a gentle way to honor their story. Understanding that pancreatic neuroendocrine tumors are a distinct, less common form of cancer — and that different cancers behave differently — is a calm, useful takeaway. Supporting free, trustworthy cancer education helps make that information available to others facing hard news.
Questions to ask a healthcare team
- What type of tumor is being discussed, and how does it differ from more common forms?
- What do its stage and grade mean for the options ahead?
- What are the goals of the treatment being described?
- What emotional and practical support is available for me and my family?